The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive, HER2-negative advanced…
TTFields therapy concomitant with gemcitabine and nab-paclitaxel is the first treatment to show a clinically meaningful and statistically significant improvement…
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd (“Avistone”), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the…